Covered recipient · General Payments record
SARAH A SKINNER
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$3,828.16
- Reported across 129 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $585.67 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $238.86 | 8 |
| GlaxoSmithKline, LLC. | $120.54 | 1 |
| Astellas Pharma US Inc | $108.64 | 1 |
| Novo Nordisk AS | $48.34 | 3 |
| ITI, Inc. | $33.99 | 2 |
| PFIZER INC. | $18.90 | 1 |
| OptiNose US, Inc. | $16.40 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $12.81 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108208948 | CMS |
| ABBVIE INC. | $21.72 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108208950 | CMS |
| ABBVIE INC. | $102.06 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108208952 | CMS |
| ABBVIE INC. | $29.67 | 06/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108208954 | CMS |
| ABBVIE INC. | $19.59 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108208956 | CMS |
| ABBVIE INC. | $18.76 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108208958 | CMS |
| ABBVIE INC. | $18.94 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108208960 | CMS |
| ABBVIE INC. | $15.31 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108208962 | CMS |
| Astellas Pharma US Inc | $108.64 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139525222 | CMS |
| GlaxoSmithKline, LLC. | $120.54 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116236031 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.22 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143605240 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.77 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143605242 | CMS |
| Novo Nordisk Inc | $17.35 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100617282 | CMS |
| Novo Nordisk Inc | $15.84 | 04/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100338395 | CMS |
| Novo Nordisk Inc | $15.15 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100491381 | CMS |
| Optinose US, Inc. | $16.40 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142181402 | CMS |
| PFIZER INC. | $18.90 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131048069 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.